Myocarditis Following SARS-CoV2 mRNA Vaccination Against COVID-19
暂无分享,去创建一个
S. Heymans | M. Metra | D. Dawson | C. Tocchetti | V. Fuster
[1] Sarah E. Wilson,et al. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada , 2022, JAMA network open.
[2] Carl A. B. Pearson,et al. Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis , 2022, The Lancet Regional Health - Europe.
[3] H. Sørensen,et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study , 2021, BMJ.
[4] R. Balicer,et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization , 2021, The New England journal of medicine.
[5] Manfred S. Green,et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel , 2021, The New England journal of medicine.
[6] P. Ponikowski,et al. COVID‐19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology , 2021, European journal of heart failure.
[7] Rosalind J Wright,et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine , 2021, Cell.
[8] D. Mann,et al. Global, Regional, and National Burden of Myocarditis From 1990 to 2017: A Systematic Analysis Based on the Global Burden of Disease Study 2017 , 2021, Frontiers in Cardiovascular Medicine.
[9] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[10] T. Kuno,et al. Myocardial injury characterized by elevated cardiac troponin and in‐hospital mortality of COVID‐19: An insight from a meta‐analysis , 2020, Journal of medical virology.